Plaque Psoriasis
Chronic inflammatory skin disease driven by immune dysregulation. MSC therapy suppresses keratinocyte hyperproliferation and the Th17 inflammatory cascade.
Plaque psoriasis is a chronic, immune-mediated skin disease characterized by sharply demarcated, erythematous, scaly plaques — most commonly on the elbows, knees, scalp, and lower back. It affects approximately 2–3% of the global population and significantly impacts quality of life through pain, itch, social stigma, and associated comorbidities including psoriatic arthritis, cardiovascular disease, and depression.
Psoriasis is driven by a dysregulated Th17 immune axis: IL-17A and IL-23 cytokines drive keratinocyte hyperproliferation and the characteristic thickened, inflamed plaques. Biologic therapies targeting IL-17, IL-23, and TNF-α have transformed psoriasis management but require continuous administration, carry infection risk, and lose efficacy over time in many patients.
MSC therapy offers a potential disease-modifying immunological intervention for psoriasis — targeting the Th17 inflammatory axis systemically rather than blocking a single cytokine.
MSCs suppress the Th17-dominant immune environment in psoriasis by reducing IL-17A, IL-22, and IL-23 production through IDO and PGE2-mediated inhibition of dendritic cell maturation and Th17 polarization. Treg expansion induced by MSC infusion helps enforce immune tolerance and restrain the self-amplifying inflammatory cascade.
In published clinical series of psoriasis patients treated with allogeneic MSC infusion, significant reductions in PASI (Psoriasis Area and Severity Index) scores were observed at 3 and 6 months, accompanied by histological improvements in skin biopsy and reductions in serum IL-17 and TNF-α levels. Some patients achieved PASI 75 or greater response — comparable to biologic therapy.
True Regen coordinates PASI scoring, skin biopsy (where available), and inflammatory marker panel at baseline and follow-up intervals to objectively document treatment response.
- Significant reduction in PASI score
- Decreased plaque area, erythema, and scaling
- Lower serum IL-17A and inflammatory markers
- Reduced itch and skin discomfort
- Potential sustained remission without continuous biologic therapy
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.